ShockWave Medical
Market Cap
US$920.7m
Last Updated
2019/09/17 00:47 UTC
Data Sources
Company Financials +
Executive Summary
ShockWave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy technology to treat calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide.
Snowflake
Fundamentals
Adequate balance sheet with limited growth.
Risks
- ShockWave Medical has significant price volatility in the past 3 months.
Similar Companies
Share Price & News
How has ShockWave Medical's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
-4.8%
NasdaqGS:SWAV
0.8%
US Medical Equipment
1.1%
US Market
1 Year Return
n/a
NasdaqGS:SWAV
9.6%
US Medical Equipment
2.1%
US Market
No trading data on SWAV.
No trading data on SWAV.
Share holder returns
| SWAV | Industry | Market | |
|---|---|---|---|
| 7 Day | -4.8% | 0.8% | 1.1% |
| 30 Day | -22.8% | 0.2% | 3.7% |
| 90 Day | -44.5% | 2.7% | 2.3% |
| 1 Year | n/a | 10.5%9.6% | 4.4%2.1% |
| 3 Year | n/a | 69.5%64.3% | 47.0%37.4% |
| 5 Year | n/a | 132.5%105.9% | 61.6%43.8% |
Price Volatility Vs. Market
How volatile is ShockWave Medical's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall St
Is ShockWave Medical (NASDAQ:SWAV) Using Debt Sensibly?3 months ago | Simply Wall St
Could ShockWave Medical, Inc.'s (NASDAQ:SWAV) Investor Composition Influence The Stock Price?Valuation
Is ShockWave Medical undervalued based on future cash flows and its price relative to the stock market?
7.71x
Price to Book (PB) ratio
Intrinsic Value Based on Future Cash Flows
ShockWave Medical's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
ShockWave Medical's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
Price Based on Earnings
ShockWave Medical is loss making, we can't compare its value to the US Medical Equipment industry average.
ShockWave Medical is loss making, we can't compare the value of its earnings to the United States of America market.
Price Based on Expected Growth
Unable to calculate PEG ratio for ShockWave Medical, we can't assess if its growth is good value.
Price Based on Value of Assets
ShockWave Medical is overvalued based on assets compared to the US Medical Equipment industry average.
Next Steps
Future Growth
How is ShockWave Medical expected to perform in the next 1 to 3 years based on estimates from 4 analysts?
14.2%
Forecasted annual earnings growth
Earnings and Revenue Growth Estimates
Future Annual Growth Analysis
ShockWave Medical's revenue is expected to grow significantly at over 20% yearly.
ShockWave Medical is not considered high growth as it is expected to be loss making for the next 1-3 years.
ShockWave Medical's revenue growth is expected to exceed the United States of America market average.
Unable to compare ShockWave Medical's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
Unable to compare ShockWave Medical's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Earnings per Share Growth Estimates
Future Return on Equity
Unable to establish if ShockWave Medical will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
Next Steps
Past Performance
How has ShockWave Medical performed over the past 5 years?
-25.1%
Last years earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
ShockWave Medical does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
Unable to compare ShockWave Medical's 1-year earnings growth to the 5-year average as it is not currently profitable.
Unable to compare ShockWave Medical's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.
Return on Equity
It is difficult to establish if ShockWave Medical has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
Return on Assets
It is difficult to establish if ShockWave Medical has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.
Return on Capital Employed
It is difficult to establish if ShockWave Medical improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Next Steps
Financial Health
How is ShockWave Medical's financial position?
Financial Position Analysis
ShockWave Medical is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
ShockWave Medical's cash and other short term assets cover its long term commitments.
Debt to Equity History and Analysis
ShockWave Medical's level of debt (12.8%) compared to net worth is satisfactory (less than 40%).
Unable to establish if ShockWave Medical's debt level has increased without past 5-year debt data.
Balance Sheet
Low level of unsold assets.
Debt is covered by short term assets, assets are 9.2x debt.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
ShockWave Medical has sufficient cash runway for 2.7 years based on current free cash flow.
Unable to confirm if ShockWave Medical has at least 1 year of cash runway based on growing free cash flows without relevant data.
Next Steps
Dividend
What is ShockWave Medical's current dividend yield, its reliability and sustainability?
Dividend Yield and Payments Analysis
Unable to evaluate ShockWave Medical's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate ShockWave Medical's dividend against the top 25% market benchmark as the company has not reported any payouts.
Unable to perform a dividend volatility check as ShockWave Medical has not reported any payouts.
Unable to verify if ShockWave Medical's dividend has been increasing as the company has not reported any payouts.
Current Payout to Shareholders
Unable to calculate sustainability of dividends as ShockWave Medical has not reported any payouts.
Future Payout to Shareholders
No need to calculate the sustainability of ShockWave Medical's dividends in 3 years as they are not expected to pay a notable one for United States of America.
Next Steps
Management
What is the CEO of ShockWave Medical's salary, the management and board of directors tenure and is there insider trading?
2.3yrs
Average management tenure
CEO
Doug Godshall (54yo)
2.3yrs
Tenure
US$510,925
Compensation
Mr. Douglas E. Godshall, also known as Doug, M.B.A., has been the Chief Executive Officer and President of Shockwave Medical, Inc. since May 10, 2017. Mr. Godshall has been an Executive Director at HeartWa ...
CEO Compensation Analysis
Doug's remuneration is lower than average for companies of similar size in United States of America.
Insufficient data for Doug to compare compensation growth.
Management Age and Tenure
2.3yrs
Average Tenure
54yo
Average Age
The tenure for the ShockWave Medical management team is about average.
Board Age and Tenure
0.7yrs
Average Tenure
54yo
Average Age
The average tenure for the ShockWave Medical board of directors is less than 3 years, this suggests a new board.
Insider Trading
No 3 month open market individual insider trading information.
Recent Insider Transactions
| Entity | Company |
| Shares | 650,000 |
| Max Price | US$34.35 |
| Entity | Company |
| Shares | 650,000 |
| Max Price | US$34.35 |
| Entity | Company |
| Shares | 30,000 |
| Max Price | US$17.00 |
Ownership Breakdown
Management Team
John Adams (72yo)
Co-Founder and Technical Advisor
- Tenure: 10.7yrs
Doug Godshall (54yo)
CEO, President & Director
- Tenure: 2.3yrs
- Compensation: US$510.93k
Daniel Hawkins (52yo)
Founder and Senior Advisor
- Tenure: 10.7yrs
Dan Puckett (55yo)
CFO & Secretary
- Tenure: 3.4yrs
- Compensation: US$429.75k
Haj Tada
General Counsel
- Tenure: 0.3yrs
Rob Williamson
Vice President of Sales
- Tenure: 2.3yrs
Rob Fletcher
Vice President of Marketing
- Tenure: 3.2yrs
Isaac Zacharias (44yo)
Chief Commercial Officer
- Tenure: 0.8yrs
- Compensation: US$907.90k
Cathy Harnett
Director of Human Resources
- Tenure: 1.3yrs
Mike Maszy
Vice President of Operations
- Tenure: 0.8yrs
Board Members
Antoine Papiernik-Berkhauer (53yo)
Director
- Tenure: 0yrs
Fred Moll (67yo)
Independent Director
- Tenure: 0yrs
- Compensation: US$15.00k
Laura Francis (52yo)
Director
- Tenure: 0.7yrs
Doug Godshall (54yo)
CEO, President & Director
- Tenure: 2.3yrs
- Compensation: US$510.93k
Colin Cahill (43yo)
Director
- Tenure: 0yrs
Jay Watkins (66yo)
Independent Director
- Tenure: 0yrs
- Compensation: US$15.00k
Ray Larkin (70yo)
Chairman
- Tenure: 0.7yrs
Company Information
ShockWave Medical, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: ShockWave Medical, Inc.
- Ticker: SWAV
- Exchange: NasdaqGS
- Founded: 2009
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$920.682m
- Shares outstanding: 28.03m
- Website: https://www.shockwavemedical.com
Number of Employees
Location
- ShockWave Medical, Inc.
- 5403 Betsy Ross Drive
- Santa Clara
- California
- 95054
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| SWAV | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | Mar 2019 |
Biography
ShockWave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy technology to treat calcified plaque in patients with peripheral vascular, coronary vascular, and he ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/09/17 00:47 |
| End of Day Share Price | 2019/09/16 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.